Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice

Journal of Immunology

Volumn 166, Issue 2, 2001, Pages 723-726

  Calida, D M ^a   Constantinescu, C ^a   Purev, E ^a   Zhang, G X ^a   Ventura, E S ^a   Lavi, E ^a   Rostami, A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; FEMALE; MALE; MOUSE; MOUSE STRAIN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0035863728     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.2.723     Document Type: Article

References (39)

1. Complement and innate immunity
2. The role of complement and complement receptors in induction and regulation of immunity
3. Complement depletion suppresses Lewis rat experimental allergic encephalomyelitis
4. The role of complement in experimental allergic encephalomyelitis
5. Clinical complementology: Recent progress and future trends
6. Complement depletion affects demyelination and inflammation in experimental allergic neuritis
7. Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis
8. Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin specific antibodies
9. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination
10. Characterization of complement-fixing antibodies to the peripheral nerve myelin in Guillain-Barré syndrome
11. Pathogenesis of neuroimmunologic diseases: Experimental models
12. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis (ADEAE)
13. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis
14. Complement-derived peptide mediators of inflammation
15. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis
16. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat
17. A novel myelin associated glycoprotein defined by a mouse monoclonal antibody
18. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex
19. + multiple sclerosis
20. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein
21. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions
22. Regulation of interleukin-12 by complement receptor 3 signalling
23. Selective suppression of interleukin-12 induction after macrophage receptor ligation
24. Multiple sclerosis with hypocomplemetaemia
25. Heterogeneity of multiple sclerosis lesions implications for the pathogenesis of demyelination
26. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
27. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide
28. The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis
29. Elimination of macrophages infiltrating the CNS suppresses EAE in rats
30. Attachment of myelin to coated pits on macrophages in EAE
31. Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions
32. C3d of complement as a molecular adjuvant: Bridging innate and native immunity
33. The Norton Lecture: A review of the oligodendrocyte in the multiple sclerosis lesion
34. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro
35. Cytokine cytotoxicity against oligodendrocytes: Apoptosis induced by lymphotoxin
36. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement
37. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β
38. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions